Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Dr. Reddy’s Laboratories (NYSE:RDY) and Alvotech (NASDAQ:ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03, which is a proposed biosimilar of Prolia ...